Relay Therapeutics shares are trading lower by 17.8% during Wednesday's session. The company priced its $200 million offering. Next: Access Our New, Shockingly Simple 'Alert System' Relay Therapeutics ...
Relay Therapeutics has maintained clinical momentum in its Phase 1/2 ReFocus trial for RLY-4008, showing promise for FGFR2-altered cholangiocarcinoma. The company's financial health is strong, with ...
Relay Therapeutics (NASDAQ:RLAY) stock rallied 41% in morning trading Monday after the drug developer reported positive interim data for its drug candidate RLY-2608 in the treatment of a certain type ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback